Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingGlobeNewsWire • Thursday
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic CancerSeeking Alpha • 04/15/24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerGlobeNewsWire • 04/11/24
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsGlobeNewsWire • 04/09/24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerGlobeNewsWire • 04/04/24
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaGlobeNewsWire • 03/28/24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/28/24
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningNewsfile Corp • 03/06/24
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateGlobeNewsWire • 03/05/24
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaGlobeNewsWire • 02/13/24
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsGlobeNewsWire • 02/05/24
Candel Therapeutics pancreatic cancer therapy awarded FDA Fast Track DesignationProactive Investors • 12/12/23
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerGlobeNewsWire • 12/12/23
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409GlobeNewsWire • 11/28/23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/09/23
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITCGlobeNewsWire • 11/04/23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerGlobeNewsWire • 11/03/23
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110GlobeNewsWire • 10/18/23
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual MeetingGlobeNewsWire • 09/27/23